6:50 PM · 15 December 2021

Vir Biotechnology stock surges on upbeat vaccine news

Vir Biotechnology (VIR.US) stock soars more than 14.0% after the drugmaker announced that recent data regarding its Covid-19 antibody therapy, which was developed in cooperation with GlaxoSmithKline (GSK.UK), showed positive effects against the omicron strain.

Vir Biotechnology (VIR.US) stock has been trading in a sideways move with some downside recently. However following positive news regarding the vaccine, stock launched today's session with a bullish price gap, nevertheless buyers failed to break above the upper limit of the consolidation zone around $54.15. As long as the price sits below, another downward impulse towards support at $34.30 may be launched. On the other hand, if bulls will manage to break above the aforementioned resistance, then upward move may accelerate towards $67.50, where March highs are located. Source: xStation5

14 September 2026, 6:34 AM

Morning Wrap: A gloomy start to the week amid rising oil prices and turmoil surrounding OpenAI 🚨

11 September 2026, 3:01 PM

US OPEN: Rebound on Wall Street despite higher Supercore inflation and a jump in yields

11 September 2026, 2:08 PM

Oracle earnings: Good, but it could have been better.

11 September 2026, 12:24 PM

Adobe Delivers Strong Results, but Falls Short of Expectations. The Market Fears the Impact of AI

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits